Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout

CONCLUSION: In this study, significant difference was not found in CV risk between allopurinol and benzbromarone initiators. In the high-CV-risk group, the incidence of CV events did not differ between allopurinol and benzbromarone initiators.PMID:35966182 | PMC:PMC9373176 | DOI:10.1177/1759720X221116409

Source: Adv Data - August 15, 2022 Category: Epidemiology Authors: Yeonghee Eun Heewon Han Kyunga Kim Seonyoung Kang Seulkee Lee Hyungjin Kim Jaejoon Lee Eun-Mi Koh Hoon-Suk Cha Source Type: research